Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (NASDAQ:CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that it has agreed to sell, by way of an underwritten public offering, pre-funded warrants, in lieu of common stock, to purchase 6,213,776 shares of common stock at a price of $5.51999 per pre-funded warrant and 126,815 shares of its common stock at a price of $5.52 per share, for expected aggregate gross proceeds of approximately $35 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the $0.00001 per share exercise price of such pre-funded warrant. The offering is expected to close on December 12, 2022, subject to customary closing conditions. All of the securities are being offered by Cabaletta.
EHang Announces Partnership And Investment With Qingdao West Coast New Area; Partnership Comes With $10M Binding Equity Investment And Potential $10M Investment In Future
GUANGZHOU, China, Dec. 23, 2022 (GLOBE NEWSWIRE) -- EHang Holdings Limited (NASDAQ:EH) ("EHang" or the "Company"), the world's leading autonomous aerial vehicle ("AAV") technology
